Phaseline

Targets › PML

PML (Protein PML): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2028.

Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. (UniProt, P29590)

Open in Phaseline: the race on PML, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Instituto do Cancer do Estado de São PauloRealgar-Indigo Naturalis Formulation (Oral Arsenic)
Arsenic trioxide induces differentiation and apoptosis of acute promyelocytic leukemia cel
PML, RARAPhase 2Acute Promyelocytic Leukemia (APL)Nov 2028

Conditions

Acute Promyelocytic Leukemia (APL) (1)

Modalities

small molecule (1)

Companies

Instituto do Cancer do Estado de São Paulo (1)

Related targets

RARA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.